Therapeutic approaches for celiac disease

Best Practice and Research: Clinical Gastroenterology

Volumn 29, Issue 3, 2015, Pages 503-521

  Plugis, Nicholas M ^a   Khosla, Chaitan ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Celiac disease; Genome wide association study; Gluten free diet; Investigational therapies; Pathogenesis

Indexed keywords

BTB AND CNC HOMOLOG 2; ENZYME INHIBITOR; FUCOSYLTRANSFERASE; GLUCOCORTICOID; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INTERLEUKIN 15; LARAZOTIDE; LEUKOCYTE ANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE KAPPA; PROTEINASE; REGULATOR OF G PROTEIN SIGNALLING 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELIAC DISEASE; DIET THERAPY; DISEASE COURSE; DRUG BIOAVAILABILITY; FOLLOW UP; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLUTEN FREE DIET; HLA SYSTEM; HOOKWORM INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; T LYMPHOCYTE; TRANSCYTOSIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

CELIAC DISEASE; DIET, GLUTEN-FREE; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84947026904     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2015.04.005     Document Type: Review

References (145)

1. A. Rubio-Tapia, R.A. Kyle, E.L. Kaplan, D.R. Johnson, W. Page, F. Erdtmann, and et al. Increased prevalence and mortality in undiagnosed celiac disease Gastroenterology 137 1 2009 88 93
2. J.Y. Kang, A.H.Y. Kang, A. Green, K.A. Gwee, and K.Y. Ho Systematic review: worldwide variation in the frequency of coeliac disease and changes over time Aliment Pharmacol Ther 38 3 2013 226 245
3. D.A.W.M. van der Windt, P. Jellema, C.J. Mulder, C.M.F. Kneepkens, and H.E. van der Horst Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review JAMA 303 17 2010 1738 1746
4. D.A. van Heel, L. Franke, K.A. Hunt, R. Gwilliam, A. Zhernakova, M. Inouye, and et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21 Nat Genet 39 7 2007 827 829
5. M. Viljamaa, K. Kaukinen, E. Pukkala, K. Hervonen, T. Reunala, and P. Collin Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study Dig Liver Dis 38 6 2006 374 380
6. K.E. Smedby, M. Akerman, H. Hildebrand, B. Glimelius, A. Ekbom, and J. Askling Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma Gut 54 1 2005 54 59
7. Y. Gao, S.Y. Kristinsson, L.R. Goldin, M. Björkholm, N.E. Caporaso, and O. Landgren Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association Gastroenterology 136 1 2009 91 98
8. L.M. Sollid, and C. Khosla Novel therapies for coeliac disease J Intern Med 269 2011 604 613
9. K. Kaukinen, K. Lindfors, and M. Mäki Advances in the treatment of coeliac disease: an immunopathogenic perspective Nat Publ Group 11 1 2013 36 44
10. N.E. Castillo, T.G. Theethira, and D.A. Leffler The present and the future in the diagnosis and management of celiac disease Gastroenterol Rep 2014 1 9
11. L.M. Sollid, and B.A. Lie Celiac disease genetics: current concepts and practical applications Clin Gastroenterol Hepatol 3 9 2005 843 851
12. E.M. Nilsen, K.E. Lundin, P. Krajci, H. Scott, L.M. Sollid, and P. Brandtzaeg Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma Gut 37 6 1995 766 776
13. P.H.R. Green, and B. Jabri Celiac disease Annu Rev Med 57 2006 207 221
14. G. Trynka, K.A. Hunt, N.A. Bockett, J. Romanos, V. Mistry, A. Szperl, and et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease Nat Genet 43 12 2011 1193 1201
15. L. Shan, I. Parrot, ø. Molberg, F. Hausch, F. Filiz, G.M. Gray, and et al. Structural basis for gluten intolerance in celiac sprue Science 297 5590 2002 2275 2279
16. W. Dieterich, T. Ehnis, M. Bauer, P. Donner, U. Volta, E.O. Riecken, and et al. Identification of tissue transglutaminase as the autoantigen of celiac disease Nat Med 3 7 1997 797 801
17. C.-Y. Kim, H. Quarsten, E. Bergseng, C. Khosla, and L.M. Sollid Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease Proc Natl Acad Sci U S A 101 12 2004 4175 4179
18. K.N. Henderson, J.A. Tye-Din, H.H. Reid, Z. Chen, N.A. Borg, T. Beissbarth, and et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease Immunity 27 1 2007 23 34
19. A. Fasano, T. Not, W. Wang, S. Uzzau, I. Berti, A. Tommasini, and et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease Lancet 355 9214 2000 1518 1519
20. A.J. Monsuur, P.I.W. de Bakker, B.Z. Alizadeh, A. Zhernakova, M.R. Bevova, E. Strengman, and et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect Nat Genet 37 12 2005 1341 1344
21. M.C. Wapenaar, A.J. Monsuur, A.A. van Bodegraven, R.K. Weersma, M.R. Bevova, R.K. Linskens, and et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis Gut 57 4 2008 463 467
22. S. Hüe, J.-J. Mention, R.C. Monteiro, S. Zhang, C. Cellier, J. Schmitz, and et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease Immunity 21 3 2004 367 377
23. B. Meresse, Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagat, T.N. Krausz, and et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease Immunity 21 3 2004 357 366
24. B. Meresse, S.A. Curran, C. Ciszewski, G. Orbelyan, M. Setty, G. Bhagat, and et al. Reprogramming of CTLs into natural killer-like cells in celiac disease J Exp Med 203 5 2006 1343 1355
25. S. Daum, R. Ipczynski, B. Heine, J.-D. Schulzke, M. Zeitz, and R. Ullrich Therapy with budesonide in patients with refractory sprue Digestion 73 1 2006 60 68
26. P. Brar, S. Lee, S. Lewis, I. Egbuna, G. Bhagat, and P.H.R. Green Budesonide in the treatment of refractory celiac disease Am J Gastroenterol 102 10 2007 2265 2269
27. C. Ciacci, L. Maiuri, I. Russo, R. Tortora, C. Bucci, C. Cappello, and et al. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/ in vitropilot study Clin Exp Pharmacol P 36 12 2009 1170 1176
28. Das P. Shalimar, V. Sreenivas, S. Datta Gupta, S.K. Panda, and G.K. Makharia Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial Dig Dis Sci 57 12 2012 3116 3125
29. H. Rautiainen, M. Färkkilä, M. Neuvonen, T. Sane, A.-L. Karvonen, H. Nurmi, and et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis Aliment Pharmacol Ther 24 11-12 2006 1545 1552
30. F. Hausch, L. Shan, N.A. Santiago, G.M. Gray, and C. Khosla Intestinal digestive resistance of immunodominant gliadin peptides Am J Physiol Gastrointest Liver Physiol 283 4 2002 G996 G1003
31. L. Shan, T. Marti, L.M. Sollid, G.M. Gray, and C. Khosla Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue Biochem J 383 Pt 2 2004 311 318
32. C. Mitea, R. Havenaar, J.W. Drijfhout, L. Edens, L. Dekking, and F. Koning Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease Gut 57 1 2008 25 32
33. J. Gass, and C. Khosla Prolyl endopeptidases Cell Mol Life Sci 64 2007 345 355
34. D. Stepniak, L. Spaenij-Dekking, C. Mitea, M. Moester, A. de Ru, R. Baak-Pablo, and et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease Am J Physiol Gastrointest Liver Physiol 291 4 2006 G621 G629
35. G.G. Pyle, B. Paaso, B.E. Anderson, D.D. Allen, T. Marti, Q. Li, and et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue Clin Gastroenterol Hepatol 3 7 2005 687 694
36. M.T. Bethune, P. Strop, Y. Tang, L.M. Sollid, and C. Khosla Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease Chem Biol 13 6 2006 637 647
37. J. Gass Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat J Pharmacol Exp Ther 318 3 2006 1178 1186
38. M.T. Bethune, J.T. Borda, E. Ribka, M.-X. Liu, K. Phillippi-Falkenstein, R.J. Jandacek, and et al. A non-human primate model for gluten sensitivity PLoS One 3 2 2008 e1614
39. J.A. Tye-Din, R.P. Anderson, R.A. Ffrench, G.J. Brown, P. Hodsman, M. Siegel, and et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo Clin Immunol 134 3 2010 289 295
40. M. Siegel, M. Garber, A. Spencer, and W. Botwick Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials Dig Dis Sci 57 2012 440 450
41. M.-L. Lähdeaho, K. Kaukinen, K. Laurila, P. Vuotikka, O.-P. Koivurova, T. Kärjä-Lahdensuu, and et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease Gastroenterology 146 7 2014 1649 1658
42. G.J. Tack, J.M.W. van de Water, M.J. Bruins, E.M.C. Kooy-Winkelaar, J. van Bergen, P. Bonnet, and et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study World J Gastroenterol 19 35 2013 5837 5847
43. J. Ehren, B. Morón, E. Martin, M.T. Bethune, G.M. Gray, and C. Khosla A food-grade enzyme preparation with modest gluten detoxification properties PLoS One 4 7 2009 e6313
44. M. Pinier, E.F. Verdu, M.N. Eddine, C.S. David, A. Vézina, N. Rivard, and et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium YGAST 136 1 2009 288 298
45. M. Pinier, G. Fuhrmann, H.J. Galipeau, N. Rivard, J.A. Murray, C.S. David, and et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues Gastroenterology 142 2 2012 316 325 e12
46. A. Tripathi, K.M. Lammers, S. Goldblum, T. Shea-Donohue, S. Netzel-Arnett, M.S. Buzza, and et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2 Proc Natl Acad Sci 106 39 2009 16799 16804
47. K.M. Lammers, R. Lu, J. Brownley, B. Lu, C. Gerard, K. Thomas, and et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3 Gastroenterology 135 1 2008 194 204 e3
48. S. Drago, R. Asmar El, M. Di Pierro, M. Grazia Clemente, A.T.A. Sapone, M. Thakar, and et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines Scand J Gastroenterol 41 4 2006 408 419
49. M. Di Pierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani, and et al. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain J Biol Chem 276 22 2001 19160 19165
50. M.G. Clemente, S. De Virgiliis, J.S. Kang, R. Macatagney, M.P. Musu, M.R. Di Pierro, and et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function Gut 52 2 2003 218 223
51. B. Paterson, K. Lammers, and M. Arrieta The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study Aliment Pharmacol Ther 26 2007 757 766
52. D.A. Leffler, C.P. Kelly, H.Z. Abdallah, A.M. Colatrella, L.A. Harris, F. Leon, and et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge Am J Gastroenterol 107 10 2012 1554 1562
53. C. Kelly, P. Green, and J. Murray Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study Aliment Pharmacol Ther 37 2013 252 262
54. D.A. Leffler, C.P. Kelly, P.H.R. Green, R.N. Fedorak, A. DiMarino, W. Perrow, and et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial Gastroenterology 2015 1 58
55. W.L.G. Oldfield, M. Larché, and A.B. Kay Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial Lancet 360 9326 2002 47 53
56. A. Verhoef, C. Alexander, A.B. Kay, and M. Larché T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity PLoS Med 2 3 2005 e78
57. G.J. Brown, J. Daveson, J.K. Marjason, R.A. Ffrench, D. Smith, M. Sullivan, and et al. A phase I study to determine safety, tolerability and bioactivity of Nexvax2 in HLA DQ2+ volunteers with celiac disease following a long-term Strict Gluten Free Diet YGAST 140 5 2011 S-437-S-438
58. J.L. Round, and S.K. Mazmanian The gut microbiota shapes intestinal immune responses during health and disease Nat Rev Immunol 9 5 2009 313 323
59. F. Shanahan Crohn's disease Lancet 359 9300 2002 62 69
60. D.K. Podolsky The current future understanding of inflammatory bowel disease Best Pract Res Cl Ha 16 6 2002 933 943
61. P. Wacklin, P. Laurikka, K. Lindfors, P. Collin, T. Salmi, M.-L.L.A. hdeaho, and et al. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet Am J Gastroenterol 109 12 2014 1933 1941
62. M.D. Angelis, C.G. Rizzello, A. Fasano, M.G. Clemente, C.D. Simone, M. Silano, and et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue probiotics and gluten intolerance Biochim Biophys Acta 1762 1 2006 80 93
63. E. Smecuol, H.J. Hwang, E. Sugai, L. Corso, A.C. Cherñavsky, F.P. Bellavite, and et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease J Clin Gastroenterol 47 2 2013 139 147
64. P. Bager, J. Arnved, S. Ronborg, J. Wohlfahrt, L.K. Poulsen, T. Westergaard, and et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial J Allergy Clin Immunol 125 1 2010 123 130
65. J. Croese, J. O'neil, J. Masson, S. Cooke, W. Melrose, D. Pritchard, and et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors Gut 55 1 2006 136 137
66. A. Daveson, D. Jones, S. Gaze, and H. McSorley Effect of hookworm infection on wheat Challenge in celiac disease - a randomised double-blinded placebo controlled trial PLoS One 6 3 2011 e17366
67. J. Croese, P. Giacomin, S. Navarro, A. Clouston, L. McCann, A. Dougall, and et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease J Allergy Clin Immunol 135 2 2015 508 516 e5
68. T. Matysiak-Budnik, I.C. Moura, M. Arcos-Fajardo, C. Lebreton, S. Ménard, C. Candalh, and et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease J Exp Med 205 1 2008 143 154
69. T. Rauhavirta, S.W. Qiao, Z. Jiang, E. Myrsky, J. Loponen, I.R. Korponay-Szabó, and et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A Clin Exp Immunol 164 1 2011 127 136
70. S. Yokoyama, N. Watanabe, N. Sato, P.-Y. Perera, L. Filkoski, T. Tanaka, and et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes Proc Natl Acad Sci 106 37 2009 15849 15854
71. G. Malamut, R.E. Machhour, N. Montcuquet, S. Martin-Lanneree, I. Dusanter-Fourt, V. Verkarre, and et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis J Clin Invest 120 6 2010 2131
72. M. Sarra, M.L. Cupi, I. Monteleone, E. Franzè, G. Ronchetti, A. Di Sabatino, and et al. IL-15 positively regulates IL-21 production in celiac disease mucosa Mucosal Immunol 6 2 2012 244 255
73. H. Lebrec, M.J. Horner, K.S. Gorski, W. Tsuji, D. Xia, W.-J. Pan, and et al. Homeostasis of human NK cells is not IL-15 dependent J Immunol 191 2013 5551 5558
74. C. Marrano, P. de Macédo, P. Gagnon, D. Lapierre, C. Gravel, and J.W. Keillor Synthesis and evaluation of novel dipeptide-bound 1, 2, 4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase Bioorg Med Chem 9 12 2001 3231 3241
75. P. de Macédo, C. Marrano, and J.W. Keillor Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors Bioorg Med Chem 10 2 2002 355 360
76. K. Choi, M. Siegel, J. Piper, L. Yuan, E. Cho, P. Strnad, and et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2 Chem Biol 12 4 2005 469 475
77. R.E. Watts, M. Siegel, and C. Khosla Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles J Med Chem 49 25 2006 7493 7501
78. E. Duval, A. Case, R.L. Stein, and G.D. Cuny Structure-activity relationship study of novel tissue transglutaminase inhibitors Bioorg Med Chem Lett 15 7 2005 1885 1889
79. C. Pardin, J.N. Pelletier, W.D. Lubell, and J.W. Keillor Cinnamoyl inhibitors of tissue transglutaminase J Org Chem 73 15 2008 5766 5775
80. S. Ozaki, E. Ebisui, K. Hamada, J.-I. Goto, A.Z. Suzuki, A. Terauchi, and et al. Potent transglutaminase inhibitors, aryl β-aminoethyl ketones Bioorg Med Chem Lett 20 3 2010 1141 1144
81. C. Klöck, X. Jin, K. Choi, C. Khosla, P.B. Madrid, A. Spencer, and et al. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2 Bioorg Med Chem Lett 21 9 2011 2692 2696
82. T.R. Diraimondo, C. Klöck, R. Warburton, Z. Herrera, K. Penumatsa, D. Toksoz, and et al. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice ACS Chem Biol 9 1 2014 266 275
83. N. Nanda Targeted inactivation of Gh/Tissue transglutaminase II J Biol Chem 276 23 2001 20673 20678
84. V. De Laurenzi, and G. Melino Gene disruption of tissue transglutaminase Mol Cell Biol 21 1 2001 148 155
85. M.L. Herman, S. Farasat, P.J. Steinbach, M.-H. Wei, O. Toure, P. Fleckman, and et al. Transglutaminase-1 gene mutations in autosomal recessive congenital ichthyosis: summary of mutations (including 23 novel) and modeling of TGase-1 Hum Mutat 30 4 2009 537 547
86. L. Muszbek, Z. Bereczky, Z. Bagoly, I. Komáromi, and É. Katona Factor XIII: a coagulation factor with multiple plasmatic and cellular functions Physiol Rev 91 3 2011 931 972
87. S.N. Stacey, P. Sulem, D.F. Gudbjartsson, A. Jonasdottir, G. Thorleifsson, S.A. Gudjonsson, and et al. Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma Hum Mol Genet 23 11 2014 3045 3053
88. C. Klöck, Z. Herrera, M. Albertelli, and C. Khosla Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2 J Med Chem 57 21 2014 9042 9064
89. J. Xia, E. Bergseng, B. Fleckenstein, M. Siegel, C.-Y. Kim, C. Khosla, and et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease Bioorg Med Chem 15 20 2007 6565 6573
90. V.V. Kapoerchan, M. Wiesner, M. Overhand, G.A. van der Marel, F. Koning, and H.S. Overkleeft Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease Bioorg Med Chem 16 4 2008 2053 2062
91. U. Jüse, Y. van de Wal, F. Koning, L.M. Sollid, and B. Fleckenstein Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library HIM 71 5 2010 475 481
92. J. Huan, R. Meza-Romero, J.L. Mooney, A.A. Vandenbark, H. Offner, and G.G. Burrows Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease Mucosal Immunol 4 1 2010 112 120
93. H.R. Gillett, I.D.R. Arnott, M. McIntyre, S. Campbell, A. Dahele, M. Priest, and et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report Gastroenterology 122 3 2002 800 805
94. G. Costantino, A. Torre della, M.A. Presti Lo, R. Caruso, E. Mazzon, and W. Fries Treatment of life-threatening type I refractory coeliac disease with long-term infliximab Dig Liver Dis 40 1 2008 74 77
95. W. Reinisch, W. de Villiers, L. Bene, L. Simon, I. Rácz, S. Katz, and et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study Inflamm Bowel Dis 16 2 2010 233 242
96. C.J. van der Woude, P. Stokkers, A.A. van Bodegraven, G. Van Assche, Z. Hebzda, L. Paradowski, and et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease Inflamm Bowel Dis 16 10 2010 1708 1716
97. K.C. Herold, S. Gitelman, C. Greenbaum, J. Puck, W. Hagopian, P. Gottlieb, and et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years Clin Immunol 132 2 2009 166 173
98. P. Wiczling, M. Rosenzweig, L. Vaickus, and W.J. Jusko Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus J Clin Pharmacol 50 5 2010 494 506
99. J.C.W. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, and et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 25 2004 2572 2581
100. S.L. Hauser, E. Waubant, D.L. Arnold, T. Vollmer, J. Antel, R.J. Fox, and et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 7 2008 676 688
101. M.D. Pescovitz, R. Bloom, J. Pirsch, J. Johnson, S. Gelone, and S.A. Villano A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients Am J Transplant 9 10 2009 2324 2330
102. L.M. Sollid, O. Molberg, S. McAdam, and K.E. Lundin Autoantibodies in coeliac disease: tissue transglutaminase-guilt by association? Gut 41 6 1997 851 852
103. H. Mei, D. Frölich, C. Giesecke, and C. Loddenkemper Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab Blood 116 24 2010 5181 5190
104. J.R. Mora, and U.H. Andrian von Differentiation and homing of IgA-secreting cells Mucosal Immunol 1 2 2008 96 109
105. R.W. Olaussen, M.R. Karlsson, K.E.A. Lundin, J. Jahnsen, P. Brandtzaeg, and I.N. Farstad Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation Gastroenterology 132 7 2007 2371 2382
106. A.D. Di Sabatino, L. Rovedatti, M.M. Rosado, R. Carsetti, G.R. Corazza, T.T. MacDonald, and et al. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin α4β7-positive T cells in blood Hum Pathol 40 5 2009 699 704
107. M.J. Walters, Y. Wang, N. Lai, T. Baumgart, B.N. Zhao, D.J. Dairaghi, and et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease J Pharmacol Exp Ther 335 1 2010 61 69
108. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, S. Hanauer, J.F. Colombel, B.E. Sands, and et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 8 2013 711 721
109. B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J.F. Colombel, W.J. Sandborn, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 8 2013 699 710
110. P.C.A. Dubois, G. Trynka, L. Franke, K.A. Hunt, J. Romanos, A. Curtotti, and et al. Multiple common variants for celiac disease influencing immune gene expression Nat Genet 42 4 2010 295 302
111. S. Senapati, J. Gutierrez-Achury, A. Sood, V. Midha, A. Szperl, J. Romanos, and et al. Evaluation of European coeliac disease risk variants in a north Indian population Eur J Hum Genet 2014 1 6
112. R. Lesourne, S. Uehara, J. Lee, K.-D. Song, L. Li, J. Pinkhasov, and et al. Themis, a T cell-specific protein important for late thymocyte development Nat Immunol 10 8 2009 840 847
113. G. Fu, J. Casas, S. Rigaud, V. Rybakin, F. Lambolez, J. Brzostek, and et al. Themis sets the signal threshold for positive and negative selection in T-cell development Nature 504 7480 2013 441 445
114. M. Chabod, C. Pedros, L. Lamouroux, C. Colacios, I. Bernard, D. Lagrange, and et al. A spontaneous mutation of the rat themis gene leads to impaired function of regulatory T cells linked to inflammatory bowel disease PLoS Genet 8 1 2012 e1002461
115. L. Jostins, S. Ripke, R.K. Weersma, R.H. Duerr, D.P. McGovern, K.Y. Hui, and et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 491 7422 2012 119 124
116. S. Sawcer, G. Hellenthal, M. Pirinen, C.C.A. Spencer, N.A. Patsopoulos, L. Moutsianas, and et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 7359 2011 214 219
117. C. Bondar, L. Plaza-Izurieta, N. Fernandez-Jimenez, I.N.A. Irastorza, S. Withoff, CEGEC, and et al. THEMIS and PTPRK in celiac intestinal mucosa: coexpression in disease and after in vitro gliadin challenge Eur J Hum Genet 22 3 2013 358 362
118. S.E. Wang, F.Y. Wu, I. Shin, S. Qu, and C.L. Arteaga Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function Mol Cell Biol 25 11 2005 4703 4715
119. A. Asano, K. Tsubomatsu, C.-G. Jung, N. Sasaki, and T. Agui A deletion mutation of the protein tyrosine phosphatase kappa (Ptprk) gene is responsible for T-helper immunodeficiency (thid) in the LEC rat Mamm Genome 18 11 2007 779 786
120. R. Iwata, N. Sasaki, and T. Agui Contiguous gene deletion of Ptprk and themis causes T-helper immunodeficiency (thid) in the LEC rat Biomed Res 31 1 2010 83 87
121. J. Sap, Y.P. Jiang, D. Friedlander, M. Grumet, and J. Schlessinger Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding Mol Cell Biol 14 1 1994 1 9
122. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, S. Sawcer, G. Hellenthal, M. Pirinen, C.C.A. Spencer, and et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 7359 2011 214 219
123. R.J. Kelly, S. Rouquier, D. Giorgi, G.G. Lennon, and J.B. Lowe Sequence and expression of a candidate for the human secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype J Biol Chem 270 9 1995 4640 4649
124. P. Wacklin, H. Mäkivuokko, N. Alakulppi, J. Nikkilä, H. Tenkanen, J. Räbinä, and et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine PLoS One 6 5 2011 e20113
125. A.S. Parmar, N. Alakulppi, P. Paavola-Sakki, K. Kurppa, L. Halme, M. Färkkilä, and et al. Association study of FUT2(rs601338) with celiac disease and inflammatory bowel disease in the Finnish population Tissue Antigens 80 6 2012 488 493
126. D.P.B. McGovern, M.R. Jones, K.D. Taylor, K. Marciante, X. Yan, M. Dubinsky, and et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease Hum Mol Genet 19 17 2010 3468 3476
127. D.J. Smyth, J.D. Cooper, J.M.M. Howson, P. Clarke, K. Downes, T. Mistry, and et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection Diabetes 60 11 2011 3081 3084
128. S. Schippa, V. Iebba, M. Barbato, G. Di Nardo, V. Totino, M.P. Checchi, and et al. A distinctive "microbial signature" in celiac pediatric patients BMC Microbiol 10 2010 175
129. P. Wacklin, K. Kaukinen, E. Tuovinen, P. Collin, K. Lindfors, J. Partanen, and et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease Inflamm Bowel Dis 19 5 2013 934 941
130. G. De Palma, J. Kamanova, J. Cinova, M. Olivares, H. Drasarova, L. Tuckova, and et al. Modulation of phenotypic and functional maturation of dendritic cells by intestinal bacteria and gliadin: relevance for celiac disease J Leukoc Biol 92 5 2012 1043 1054
131. M.A. Ferreira, M.C. Matheson, D.L. Duffy, G.B. Marks, J. Hui, P. Le Souëf, and et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma Lancet 378 9795 2011 1006 1014
132. A. Franke, D.P.B. McGovern, J.C. Barrett, K. Wang, G.L. Radford-Smith, T. Ahmad, and et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Nat Genet 42 12 2010 1118 1125
133. Y. Jin, S.A. Birlea, P.R. Fain, T.M. Ferrara, S. Ben, S.L. Riccardi, and et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo Nat Genet 44 6 2012 676 680
134. J.D. Cooper, D.J. Smyth, A.M. Smiles, V. Plagnol, N.M. Walker, J.E. Allen, and et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci Nat Genet 40 12 2008 1399 12401
135. K. Igarashi, K. Ochiai, A. Itoh-Nakadai, and A. Muto Orchestration of plasma cell differentiation by Bach2 and its gene regulatory network Immunol Rev 261 1 2014 116 125
136. R. Roychoudhuri, K. Hirahara, K. Mousavi, D. Clever, C.A. Klebanoff, M. Bonelli, and et al. BACH2 represses effector programs to stabilize treg-mediated immune homeostasis Nature 498 7455 2013 506 510
137. V. Kumar, J. Gutierrez-Achury, K. Kanduri, R. Almeida, B. Hrdlickova, D.V. Zhernakova, and et al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels Hum Mol Genet 24 2 2014 397 409
138. D.J. Smyth, V. Plagnol, N.M. Walker, J.D. Cooper, K. Downes, J.H.M. Yang, and et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease N Engl J Med 359 26 2008 2767 2777
139. International Multiple Sclerosis Genetics Consortium (IMSGC), W.S. Bush, S.J. Sawcer, P.L. De Jager, J.R. Oksenberg, J.L. McCauley, and et al. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come Am J Hum Genet 86 4 2010 621 625
140. K.A. Hunt, A. Zhernakova, G. Turner, G.A.R. Heap, L. Franke, M. Bruinenberg, and et al. Newly identified genetic risk variants for celiac disease related to the immune response Nat Genet 40 4 2008 395 402
141. C. Moratz, V.H. Kang, K.M. Druey, C.S. Shi, A. Scheschonka, P.M. Murphy, and et al. Regulator of G protein signaling 1 (RGS1) markedly impairs Gi alpha signaling responses of B lymphocytes J Immunol 164 4 2000 1829 1838
142. C. Moratz, J.R. Hayman, H. Gu, and J.H. Kehrl Abnormal B-cell responses to chemokines, disturbed plasma cell localization, and distorted immune tissue architecture in Rgs1-/- mice Mol Cell Biol 24 13 2004 5767 5775
143. D.L. Gibbons, L. Abeler-Dörner, T. Raine, I.-Y. Hwang, A. Jandke, M. Wencker, and et al. Cutting Edge: regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential J Immunol 187 5 2011 2067 2071
144. Burdett T, Hall PN, Hasting E, Hindorff LA, Junkins HA, Klemm AK, et al. The NHGRI-EBI catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies [accessed 14.02.15].
145. M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, and et al. Circos: an information aesthetic for comparative genomics Genome Res 19 9 2009 1639 1645